Dermata Therapeutics, Inc. (DRMA) Financials

DRMA Assets vs Liabilities

DateAssetsLiabilities
June 30, 2026 5.3 million 1.8 million
March 31, 2026 7.5 million 1.1 million
Dec. 31, 2025 7.9 million 1.6 million
Sept. 30, 2025 5.1 million 1.1 million

DRMA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -2.5 million 41780
March 31, 2026 -2.5 million 43278
Dec. 31, 2025 -1.3 million 29469
Sept. 30, 2025 -1.8 million 37841

DRMA Net Income

No data available :(

DRMA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 4.4 million - -
March 31, 2026 6.9 million - -
Dec. 31, 2025 7.5 million - -
Sept. 30, 2025 4.7 million - -

DRMA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 4.0 million
March 31, 2026 3.9 million
Dec. 31, 2025 1.2 million
Sept. 30, 2025 1.0 million

DRMA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 110667 212563 428966 -
March 31, 2026 - 383724 1.5 million 206333
Dec. 31, 2025 3 526620 1.4 million -
Sept. 30, 2025 5 504387 1.3 million 472940

DRMA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -

DRMA

Price: $1.19

52 week price:
0.95
6.23

Earnings Per Share: -4.20 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 329600

Market Capitalization: 838315

Links: